ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Febbraio 2024 - 10:30PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the compensation committee of the Company’s
Board of Directors (the “Compensation Committee”) approved,
effective as of January 31, 2024, the grant of restricted stock
units (“RSUs”) covering 68,940 shares of ImmunoGen’s common stock
under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as
amended (the “Inducement Plan”) to eleven new employees.
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
ImmunoGen (or following a bona fide period of non-employment), as
an inducement material to such individual’s entering into
employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
Each RSU will vest as to 25% of the shares underlying the RSU
award on the first anniversary of the grant date and as to an
additional 25% of the shares underlying the RSU award annually
thereafter for the next three years, subject to the employee’s
continued employment on each vesting date. Each RSU is subject to
the terms and conditions of the Inducement Plan and the terms and
conditions of an RSU agreement covering the grants.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates to improve outcomes for cancer patients. By generating
targeted therapies with enhanced anti-tumor activity and favorable
tolerability profiles, we aim to disrupt the progression of cancer
and offer our patients more good days. We call this our commitment
to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240201135762/en/
INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600
anabel.chan@immunogen.com
MEDIA ImmunoGen Courtney O’Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Nov 2023 a Nov 2024